磷脂酰乙醇检测未充分报告饮酒及优化脂肪性肝病亚分类的临床价值
本研究为前瞻性研究的横断面分析,纳入391名超重/肥胖且磁共振质子密度脂肪分数≥5%定义的脂肪性肝病社区成人,评估磷脂酰乙醇(PEth)检测未充分报告饮酒的患病率及其预测因素,并探讨PEth对脂肪性肝病亚分类的优化作用。结果显示15.9%(95%CI 12.2%-19.5%)的脂肪性肝病患者未充分报告饮酒,联合PEth后代谢酒精相关肝病和酒精相关肝病诊断分别增加4倍和3倍。
要点
- 15.9%(95%CI 12.2%-19.5%)的脂肪性肝病患者未充分报告饮酒。
- 男性、无2型糖尿病和白种人是未充分报告饮酒的最强独立因素。
- 联合PEth使代谢酒精相关肝病和酒精相关肝病诊断分别增加4倍和3倍。
核心结论
- PEth可客观量化饮酒,结合临床病史有助于识别脂肪性肝病亚类,减少诊断误分类。
研究设计与样本
- 前瞻性研究的横断面分析,纳入391名居住于南加州的超重/肥胖且磁共振质子密度脂肪分数≥5%定义的脂肪性肝病社区成人,参与者接受标准化临床研究访视,包括MRI评估和PEth检测。
主要发现
- 队列平均(标准差)年龄51(13)岁,平均(标准差)BMI 33(6)kg/m2。
- 随着PEth水平升高,胰岛素抵抗和糖化血红蛋白降低,而血压和高密度脂蛋白胆固醇升高。
- 15.9%(95%CI 12.2%-19.5%)的脂肪性肝病患者未充分报告饮酒。
- 男性、无2型糖尿病和白种人是该人群中与饮酒未充分报告相关的最强独立因素。
- 在自报饮酒基础上联合PEth使代谢酒精相关肝病诊断增加4倍、酒精相关肝病诊断增加3倍;男性、天冬氨酸氨基转移酶、平均红细胞体积、高密度脂蛋白胆固醇和MRI衍生的质子密度脂肪分数是与更高PEth相关的最强独立因素。
关键数值与推荐
- 脂肪性肝病定义为MRI衍生质子密度脂肪分数≥5%。
- PEth与自报饮酒呈中度正相关,但一致性低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The 2023 subclassification of steatotic liver disease (SLD) relies on self-reported alcohol use, which lacks diagnostic precision in routine clinical practice. Phosphatidylethanol (PEth) is a quantitative, objective alcohol biomarker with high sensitivity and specificity. In this study, we aimed to estimate the prevalence of underreported alcohol use, identify its independent predictors, and enhance SLD subclassification using PEth in a large, population-based cohort of individuals with overweight/obesity and SLD from the US. METHODS: This is a cross-sectional analysis of a prospective study including 391 community-dwelling adults with overweight/obesity and SLD, as defined by MRI-derived proton density fat fraction ≥5%, residing in Southern California. Participants underwent a standardized clinical research visit, including MRI assessment and PEth testing. RESULTS: In this cohort, the mean (SD) age and BMI were 51 (13) years and 33 (6) kg/m2, respectively. As PEth levels increased, insulin resistance and hemoglobin A1c decreased, while blood pressure and high-density lipoprotein cholesterol increased. Of individuals with SLD, 15.9% (95% CI 12.2%-19.5%) underreported their alcohol consumption. Male sex, absence of type 2 diabetes, and White race were the strongest independent factors associated with alcohol underreporting in this population. The use of PEth in addition to self-reported alcohol use resulted in 4-fold and 3-fold increases in MetALD and ALD diagnoses, respectively. Male sex, aspartate aminotransferase, mean corpuscular volume, high-density lipoprotein cholesterol, and MRI-derived proton density fat fraction were the strongest independent factors associated with higher PEth. PEth and self-reported alcohol use showed a moderate positive correlation, while the agreement was low. CONCLUSIONS: PEth may objectively quantify alcohol use and help identify SLD subcategories alongside clinical history, reducing diagnostic misclassification. IMPACT AND IMPLICATIONS: The current subclassification of steatotic liver disease (SLD) relies on self-reported alcohol use, which is frequently limited by patient underreporting, potentially leading to diagnostic misclassification. In this study of 391 community-dwelling adults with overweight/obesity and SLD assessed by advanced MRI methods, we found that 15.9% (95% CI 12.2%-19.5%) of individuals with SLD underreported alcohol use based on their phosphatidylethanol (PEth) levels. Male sex, absence of type 2 diabetes, and White race were the strongest independent factors associated with alcohol underreporting in this population. The incorporation of PEth alongside self-reported alcohol use resulted in a 4-fold increase in MetALD diagnoses and a 3-fold increase in ALD diagnoses. These findings support the clinical utility of PEth as a direct, quantitative, objective alcohol biomarker which may help clinicians identify SLD subcategories and differentiate between its metabolic and alcohol-related etiologies.
引用
- Tavaglione F, Díaz LA, Ajmera V, et al. Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification. J Hepatol. 2025. PMID: 40517819. doi:10.1016/j.jhep.2025.05.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。